New Issue: Barclays prices $250,000 17.5% reverse convertibles linked to Amylin Pharmaceuticals

New York, June 29 - Barclays Bank plc priced $250,000 of 17.5% reverse convertible notes due Dec. 30, 2010 linked to Amylin Pharmaceuticals, Inc shares, according to a 424B2 filing with the Securities and Exchange Commission.

The payout at maturity will be par in cash unless Amylin Pharmaceuticals shares fall below the protection price of $12.55, 65% of the initial price of $19.30, during the life of the notes and finish below the initial price in which case the payout will be 51.813472 shares of Amylin Pharmaceuticals stock.

Barclays Capital is the agent.

Issuer:	Barclays Bank plc
Issue:	Reverse convertible notes
Underlying stock:	Amylin Pharmaceuticals, Inc (Symbol: AMLN)
Amount:	$250,000
Maturity:	Dec. 30, 2010
Coupon:	17.5%, payable monthly
Price:	Par
Payout at maturity:	Par in cash unless Amylin Pharmaceuticals shares fall below the protection price of $12.55, 65% of the initial price, and finish below the initial price, in which case 51.813472 shares of Amylin Pharmaceuticals stock
Initial price:	$19.30
Protection price:	$12.55, 65% of $19.30
Exchange ratio:	51.813472
Pricing date:	June 25
Settlement date:	June 30
Agent:	Barclays Capital
Fees:	1.625%
Cusip:	06740LZG3

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.